https://www.aigom.it/wp-content/uploads/2025/04/8-APRILE.png1301960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-08 07:56:242025-04-08 07:56:24CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2025/04/1aprile.png15431073Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-01 08:32:102025-04-01 08:32:10FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2025/03/25.3.png1215960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-25 09:16:212025-03-25 09:16:21PHASE II EFFICACY AND SAFETY OF 80 MG OSIMERTINIB IN PATIENTS WITH LEPTOMENINGEAL METASTASES ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (BLOSSOM).
https://www.aigom.it/wp-content/uploads/2025/03/IMM18.3.png1136960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-18 08:35:452025-03-18 08:35:45OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2025/03/LOC.11.3.png1342960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-11 08:47:002025-03-11 08:47:00FIRST-LINE NIVOLUMAB PLUS RELATLIMAB VERSUS NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA: AN INDIRECT TREATMENT COMPARISON USING RELATIVITY-047 AND CHECKMATE 067 TRIAL DATA.
https://www.aigom.it/wp-content/uploads/2025/03/art4.3.png1242960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 08:49:132025-03-04 08:58:47FINAL, 10-YEAR OUTCOMES WITH NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA.
https://www.aigom.it/wp-content/uploads/2025/02/25.02.png1353960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-25 08:25:392025-02-25 08:25:39BREAST CANCER BRAIN METASTASIS: A COMPREHENSIVE REVIEW.
https://www.aigom.it/wp-content/uploads/2025/02/ART18.2.png1201960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-18 08:50:152025-02-18 08:50:15SURVIVAL WITH CEMIPLIMAB IN RECURRENT CERVICAL CANCER.
https://www.aigom.it/wp-content/uploads/2025/02/ART11.2.png1471960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-11 08:40:452025-02-11 08:40:45DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER FROM THE PHASE III ARANOTE TRIAL.
https://www.aigom.it/wp-content/uploads/2025/02/ART.04.02.png1254960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-03 09:18:082025-02-03 09:18:08CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN NON-SMALL CELL LUNG CANCER WITH PD-L1≥ 1 %: A SUBGROUP ANALYSIS FROM THE EMPOWER-LUNG 3 PART 2 TRIAL.
